Abstract
BACKGROUND: Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction. In a phase 1-2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients with ITP. METHODS: In phase 1, 24 patients who had received at least one treatment for ITP were assigned to escalating-dose cohorts of 4 patients each and given two identical doses of AMG 531 (0.2 to 10 μg per kilogram of body weight). In phase 2, 21 patients were randomly assigned to receive six weekly subcutaneous injections of AMG 531 (1, 3, or 6 μg per kilogram) or placebo. The primary objective was to assess the safety of AMG 531; the secondary objective was to evaluate platelet counts during and after treatment. RESULTS: No major adverse events that could be attributed directly to AMG 531 occurred during the treatment period; 4 of 41 patients had transient post-treatment worsening of thrombocytopenia. In phase 1, a platelet count that was within the targeted range (50,000 to 450,000 per cubic millimeter) and at least twice the baseline count was achieved in 4 of 12 patients given 3, 6, or 10 μg of AMG 531 per kilogram. Overall, a platelet count of at least 50,000 per cubic millimeter was achieved in 7 of 12 patients, including 3 with counts exceeding 450,000 per cubic millimeter. Increases in the platelet count were dose-dependent; mean peak counts were 163,000, 309,000, and 746,000 per cubic millimeter with 3, 6, and 10 μg of AMG 531 per kilogram, respectively. In phase 2, the targeted platelet range was achieved in 10 of 16 patients treated with 1 or 3 μg of AMG 531 per kilogram per week for 6 weeks. Mean peak counts were 135,000, 241,000, and 81,000 per cubic millimeter in the groups that received the 1-μg dose, the 3-μg dose, and placebo, respectively. CONCLUSIONS: AMG 531 caused no major adverse events and increased platelet counts in patients with ITP. (ClinicalTrials.gov number, NCT00111475.)
| Original language | English |
|---|---|
| Pages (from-to) | 1672-1681 |
| Number of pages | 10 |
| Journal | New England Journal of Medicine |
| Volume | 355 |
| Issue number | 16 |
| DOIs | |
| State | Published - Oct 19 2006 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. / Bussel, James B.; Kuter, David J.; George, James N.; McMillan, Robert; Aledort, Louis M.; Conklin, George T.; Lichtin, Alan E.; Lyons, Roger M.; Nieva, Jorge; Wasser, Jeffrey S.; Wiznitzer, Israel; Kelly, Reggie; Chen, Chien Feng; Nichol, Janet L.
In: New England Journal of Medicine, Vol. 355, No. 16, 19.10.2006, p. 1672-1681.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
AU - Bussel, James B.
AU - Kuter, David J.
AU - George, James N.
AU - McMillan, Robert
AU - Aledort, Louis M.
AU - Conklin, George T.
AU - Lichtin, Alan E.
AU - Lyons, Roger M.
AU - Nieva, Jorge
AU - Wasser, Jeffrey S.
AU - Wiznitzer, Israel
AU - Kelly, Reggie
AU - Chen, Chien Feng
AU - Nichol, Janet L.
PY - 2006/10/19
Y1 - 2006/10/19
N2 - BACKGROUND: Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction. In a phase 1-2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients with ITP. METHODS: In phase 1, 24 patients who had received at least one treatment for ITP were assigned to escalating-dose cohorts of 4 patients each and given two identical doses of AMG 531 (0.2 to 10 μg per kilogram of body weight). In phase 2, 21 patients were randomly assigned to receive six weekly subcutaneous injections of AMG 531 (1, 3, or 6 μg per kilogram) or placebo. The primary objective was to assess the safety of AMG 531; the secondary objective was to evaluate platelet counts during and after treatment. RESULTS: No major adverse events that could be attributed directly to AMG 531 occurred during the treatment period; 4 of 41 patients had transient post-treatment worsening of thrombocytopenia. In phase 1, a platelet count that was within the targeted range (50,000 to 450,000 per cubic millimeter) and at least twice the baseline count was achieved in 4 of 12 patients given 3, 6, or 10 μg of AMG 531 per kilogram. Overall, a platelet count of at least 50,000 per cubic millimeter was achieved in 7 of 12 patients, including 3 with counts exceeding 450,000 per cubic millimeter. Increases in the platelet count were dose-dependent; mean peak counts were 163,000, 309,000, and 746,000 per cubic millimeter with 3, 6, and 10 μg of AMG 531 per kilogram, respectively. In phase 2, the targeted platelet range was achieved in 10 of 16 patients treated with 1 or 3 μg of AMG 531 per kilogram per week for 6 weeks. Mean peak counts were 135,000, 241,000, and 81,000 per cubic millimeter in the groups that received the 1-μg dose, the 3-μg dose, and placebo, respectively. CONCLUSIONS: AMG 531 caused no major adverse events and increased platelet counts in patients with ITP. (ClinicalTrials.gov number, NCT00111475.)
AB - BACKGROUND: Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction. In a phase 1-2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients with ITP. METHODS: In phase 1, 24 patients who had received at least one treatment for ITP were assigned to escalating-dose cohorts of 4 patients each and given two identical doses of AMG 531 (0.2 to 10 μg per kilogram of body weight). In phase 2, 21 patients were randomly assigned to receive six weekly subcutaneous injections of AMG 531 (1, 3, or 6 μg per kilogram) or placebo. The primary objective was to assess the safety of AMG 531; the secondary objective was to evaluate platelet counts during and after treatment. RESULTS: No major adverse events that could be attributed directly to AMG 531 occurred during the treatment period; 4 of 41 patients had transient post-treatment worsening of thrombocytopenia. In phase 1, a platelet count that was within the targeted range (50,000 to 450,000 per cubic millimeter) and at least twice the baseline count was achieved in 4 of 12 patients given 3, 6, or 10 μg of AMG 531 per kilogram. Overall, a platelet count of at least 50,000 per cubic millimeter was achieved in 7 of 12 patients, including 3 with counts exceeding 450,000 per cubic millimeter. Increases in the platelet count were dose-dependent; mean peak counts were 163,000, 309,000, and 746,000 per cubic millimeter with 3, 6, and 10 μg of AMG 531 per kilogram, respectively. In phase 2, the targeted platelet range was achieved in 10 of 16 patients treated with 1 or 3 μg of AMG 531 per kilogram per week for 6 weeks. Mean peak counts were 135,000, 241,000, and 81,000 per cubic millimeter in the groups that received the 1-μg dose, the 3-μg dose, and placebo, respectively. CONCLUSIONS: AMG 531 caused no major adverse events and increased platelet counts in patients with ITP. (ClinicalTrials.gov number, NCT00111475.)
UR - http://www.scopus.com/inward/record.url?scp=33750035507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750035507&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa054626
DO - 10.1056/NEJMoa054626
M3 - Article
C2 - 17050891
AN - SCOPUS:33750035507
VL - 355
SP - 1672
EP - 1681
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 16
ER -